Overexpression of the transcription factor POU4F1 (POU Class 4 Homeobox 1) contributed to the resistance to BRAFi in vemurafenib-treated melanoma cells by increasing MEK expression and activating MEK/ERK signaling. Here, MAP2K7 is linked to melanoma.